Mizuho Maintains Outperform on Autolus Therapeutics, Lowers Price Target to $10

Benzinga Newsdesk www.benzinga.com Negative 93.3%

Neg 93.3% Neu 0% Pos 0%

Mizuho analyst Salim Syed maintains Autolus Therapeutics (NASDAQ:AUTL) with a Outperform and lowers the price target from $12 to $10.